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OBJECTIVE — Cerebrovascular reactivity impairment was reported as a marker of cerebral
microangiopathy in long-term type 1 diabetes. Intima-media complex thickening reﬂects early
stages of macroangiopathy in type 1 diabetes. The analysis of the relationship between these
variablesandothermicroangiopathiccomplicationsmightserveasabeneﬁcialindicatorforearly
prophylaxis in these patients.
RESEARCH DESIGN AND METHODS — Vasomotor reactivity reserve (VMRr) and
breath-holdingindex(BHI)ofthemiddlecerebralarteryweremeasuredwithtranscranialDopp-
lerin59patients(medianage32.0years,range20–51,36females)withtype1diabetes,without
history of cerebrovascular events, and 30 healthy control subjects (median age 31.5 years, range
25–39, 15 females). The relationships between the presence of selected vascular complications
of type 1 diabetes and biochemical parameters, intima-media thickness (IMT), and VMRr and
BHI in patients were analyzed.
RESULTS — VMRr and BHI were lower in patients with type 1 diabetes when compared with
healthysubjects(81.5vs.100%,P0.01,and1.6vs.2.2,P0.04,respectively),whereasIMT
was signiﬁcantly higher in patients then in healthy control subjects (0.36 vs. 0.30 mm, P 
0.001).However,noassociationofIMTwithVMRrwasfound.Wefoundasigniﬁcantreduction
of VMRr and BHI in patients with diabetic nephropathy.
CONCLUSIONS — The presence of diabetic nephropathy, but not IMT, can be regarded as
an indicator of cerebral microangiopathy severity in patients with type 1 diabetes.
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S
troke caused by small-vessel disease
can be observed more frequently in
patients with diabetes than in the
general population (1). The presence of
systemic microvascular complications of
diabetes, especially nephropathy and ret-
inopathy, also increases the risk of stroke
and silent cerebral ischemia (2,3). Cere-
bral microangiopathy can be reﬂected by
cerebrovascular reactivity (CVR) impair-
ment (4). Previous studies on CVR in pa-
tients with type 1 diabetes have shown a
reducedCVRinchildrenwithdiabeticke-
toacidosis and in adults with long dura-
tionoftype1diabetes(5,6).Astudyusing
the intravenous 133 Xenon method
showed CVR impairment in patients with
type1diabeteswithnephropathyandret-
inopathy (7). In contrast, a single report
revealed preserved CVR in asymptomatic
adolescents with type 1 diabetes (8).
In spite of a high incidence of carotid
artery disease and a high annual rate of
intima-media thickness (IMT) progres-
sion in patients with type 1 diabetes, no
information exists on the correlation be-
tween IMT and CVR to date (9–12). A
single report published recently sug-
gested the lack of such correlation in pa-
tients with type 2 diabetes (13). It is not
clear if this result can be extrapolated to
patients with type 1 diabetes.
Therefore, the aim of our study was
to evaluate CVR in patients with type 1
diabetes without advanced diabetes com-
plications and to assess the relationship be-
tween the CVR and type 1 diabetes course
and the presence of diabetic macro- and
microangiopathy.
RESEARCH DESIGN AND
METHODS— The study population
consisted of 59 patients with type 1 dia-
betes(36womenand23men,medianage
32.0 years, range limits 20–51 years), re-
cruited from the Regional Diabetological
Centre of our university and 30 healthy
volunteers (15 women and 15 men, me-
dian age 31.5 years, range limits 20–39
years). We included patients with mini-
mal diabetes duration of 2 years and who
werefreeoffocalneurologicaldeﬁcits,re-
spiratory tract disease (at present and in
history), and renal insufﬁciency. We ex-
cluded patients with past cerebrovascular
events or head trauma, those who were
pregnant, and those with incidents of hy-
poglycemia within 30 days before the
study. Current and past smokers were
alsoexcludedinbothpatientsandcontrol
groups, as well as heavy drinkers and us-
ers of any hormonal therapy within 30
days before study.
All examinations were performed at
the same time of the day (between 10:00
A.M. and 2:00 P.M.). All study subjects
were asked to stop drinking coffee on ex-
amination day and to avoid sleep depri-
vation and fasting.
The study protocol included history
taking, neurological examination, ex-
tracranial and transcranial ultrasound,
fundoscopy, and laboratory testing. The
study protocol was approved by the Med-
icalEthicsCommitteeoftheMedicalUni-
versity of Gdan ´sk (NKEBN/3/2005).
Upon entry, each participant gave in-
formed consent.
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Patient history was obtained, including
the information on past and current dis-
orders as well as on comorbid conditions.
Theweightandheightwererecordedand
expressed as the BMI. Focal neurological
deﬁcitswereexcludedbyneurologicalex-
aminationperformedbyneurologistscer-
tiﬁed by the Polish Neurological Society.
Diabetic neuropathy was diagnosed with
the criteria of neuropathy symptoms
score, based on patients’ complaints and
neuropathic deﬁcits found on neurologi-
cal examination (14). Hypertension was
diagnosed if two consecutive measure-
mentsofsystolicanddiastolicbloodpres-
sures exceeded 130 and 80 mmHg,
respectively, or if antihypertensive medi-
cationwasused.Laboratoryexaminations
in patients with type 1 diabetes included
measurements of circadian urinary pro-
tein/microalbuminuria, total serum cho-
lesterol, and A1C. The biochemical
examinations were performed 1 month
(7days)beforetranscranialDopplerex-
amination(TCD).Hyperlipidemiawasdi-
agnosed if total cholesterol and/or
triglycerides exceeded 175 and 150 mg/dl,
respectively, or if cholesterol/triglyceride-
lowering medications were used.
BasedonAmericanDiabetesAssoci-
ation criteria, microalbuminuria was
deﬁned as excretion of 30–300 mg al-
bumin/24 h on two of three urine collec-
tions repeated at intervals of up to 6
months (15). Clinical albuminuria or
“overtnephropathy”pertheAmericanDi-
abetesAssociationrecommendationscor-
responded to protein excretion over 300
mg/24 h. In our patients, quantitative
measurements of urine protein excretion
in a sample obtained from 24-h urine col-
lection were used to assess the severity of
proteinuria. Albumin concentrations in
urineweremeasuredwiththeturbidimet-
ric method. We included in the statistical
analysisthemeasurementthatwasclosest
in time to the TCD study.
Fundoscopy
Retinopathy was recognized on fundos-
copy performed by an ophthalmologist
certiﬁed by the Polish Ophthalmic Soci-
ety.Gradingwasmadewiththeuseofthe
Stages of Diabetic Retinopathy of the
American Academy of Ophthalmology.
Previous therapy with photocoagulation
was also recognized as a marker of dia-
betic retinopathy (16).
IMT measurement
TheIMTinbothcarotidarterieswasmea-
sured using an Aloka 5000 ultrasound
machine (ALOKA, Japan) equipped with
a linear probe with central working fre-
quency of 7.5 MHz and range limits of
5–10 MHz, after standard examination of
both carotid arteries. During each exami-
nation, the distal 2-cm-long segment of
the common carotid artery in two dif-
ferent (anterior-posterior and lateral)
longitudinal projections was assessed
bilaterally.TheﬁnalvalueofIMTwascal-
culated as a mean of four measurements
(two projections, both sides). IMT was
measured ofﬂine using a semiautomatic
method (Carotid Measure System) per-
formed by one investigator (K.B.K., 12
years of experience) who was blinded to
the patients’ history.
Transcranial Doppler examination
The middle cerebral artery ﬂow parame-
ters were measured using the MultiDop
T2 ultrasound machine (DWL Elektro-
nische Systeme, Singen, Germany),
equipped with the 2-MHz pulse wave
probe. Velocity measurements were per-
formedsimultaneouslyinbothmiddlece-
rebral arteries with the use of a two-
channel monitoring kit: two probes
2-MHzpulsewave,theﬁxationband,and
the monitoring program (MF version
8.27 l; DWL Elektronische Systeme). The
physiologicaltechniquesofprovokingce-
rebrovascular reactivity by changes of
pCO2 were applied according to the pub-
lished standards (17,18). During the CO2
reactivity test, the CO2 content in expired
air (end tidal CO2 concentration) was
monitored continuously (capnograph;
Datex, Normocap, Finland). Before and
afterthetests,thesystemicbloodpressure
and heart rate were measured. The vaso-
motor reactivity reserve (VMRr), ex-
pressed in percent change from baseline,
and breath-holding index (BHI) were cal-
culating according to the standard proto-
col published previously (17,18). The
median values of arithmetical means of
velocity measurements at rest (rest
Vmean), VMRr, BHI, pulsatility index (PI),
and resistance index (RI) of both middle
cerebral arteries were used for further
analyses.
Reproducibility
In nine healthy volunteers, the reproduc-
ibility of VMRr measurement was
checked. The unbiased intraclass correla-
tion coefﬁcient for the results of two con-
secutive measurements of VMRr was
considered acceptable (intraclass correla-
tion coefﬁcient  0.89, P  0.007).
Statistical analysis
All the analyses were performed with
STATISTICA,version7.1(StatSoft,2005;
Table 1—Characteristics of patients with type 1 diabetes and healthy control subjects
Patients
Healthy control
subjects P
n 59 30 —
Age (years) 32.0 (20–51) 31.5 (25–39) 0.37
F:M ratio 36:23 15:15 0.32; 
2 M-L  0.98
BMI (kg/m
2) 23.9 (20–31.6) 23.2 (19.2–33) 0.18
Systolic blood pressure (mmHg) 120 (98–145) 120 (100–140) 0.68
Diastolic blood pressure (mmHg) 80 (68–98) 77 (60–94) 0.11
Heart rate (beats/min) 73 (55–98) 69 (50–88) 0.3
Hyperlipidemia (%) 61.0
Hypertension (%) 16.0
Neuropathy (%) 20.3
Retinopathy (%) 44.1
Range of albuminuria (mg/day) 0.45–2,029
Microalbuminuria (%) 13.6
Overt nephropathy (%) 3.3
Type 1 diabetes duration (years) 15.0  3–33
A1C (%) 7.8 (5.9–12)
Circadian insulin demand (units) 49 (19–82)
ACE inhibition or angiotensin
receptor blocker treatment (%)
15.2
Statin treatment (%) 6.7
Data are median (range), arithmetic mean  SD, or percentage of patients. M-L, maximum likelihood.
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tests were performed to analyze the dis-
tribution of continuous variables. Differ-
encesbetweengroupswereanalyzedwith
the Student’s t test in case of normally
distributed variables (type 1 diabetes du-
ration) or with Mann-Whitney U test in
case of non–normally distributed vari-
ables (age, BMI, diastolic and systolic
bloodpressure,heartrate,VMRr,BHI,PI,
RI, end tidal CO2 concentration, and
IMT). The 
2 test was used to compare a
proportion of females to males in groups.
CorrelationwasassessedbytheSpearman
rank correlation test. Multivariable linear
regression analysis was used to assess
confounders of CVR in patients with type
1 diabetes. The level of P  0.05 was re-
garded as statistically signiﬁcant.
RESULTS— All patients and volun-
teers were free of coronary heart disease,
diabetic foot, orthostatic hypotension,
chronic renal insufﬁciency, or hemody-
namically signiﬁcant stenosis (50%) of
extra-andintracranialcerebralarteries,as
determined by physical check, biochem-
ical analysis, and carotid and transcranial
ultrasound, respectively. There was no
signiﬁcant difference regarding age, sex,
BMI, blood pressure, and heart rate be-
tween patients and healthy control sub-
jects (Table 1).
The median values of VMRr and BHI
were signiﬁcantly lower in patients than
in the healthy control subjects. Both
groups did not differ regarding values of
resting Vmean, PI, and RI. The end tidal
CO2 concentrations did not differ be-
tween the groups, both during hyperven-
tilation and breath holding. The median
value of IMT in patients was signiﬁcantly
higher in comparison to respective values
in healthy control subjects (Table 2). We
found no signiﬁcant correlations between
VMRr or BHI values and age, diabetes
duration,dailyinsulindemand,A1Ccon-
centrations, total serum cholesterol, tri-
glyceride level, or IMT in patients with
type 1 diabetes. Furthermore, no signiﬁ-
cant correlations between IMT and VMRr
or BHI were seen in healthy control
subjects.
Taking together both microalbumin-
uria and overt nephropathy into one
group, an analysis showed a signiﬁcant
reduction of CVR values in the presence
of diabetic nephropathy (Table 3). After
exclusion of two patients with overt ne-
phropathy, VMRr remained impaired in
patients with microalbuminuria when
compared with individuals without mi-
croalbuminuria (71.0 vs. 87.5%, P 
0.03).
The median age in patients with ne-
phropathy was 30 years (minimum 27
years, maximum 45 years), while in pa-
tients without nephropathy, it was 32
years (minimum 20, maximum 51). The
age difference between the two groups
was not signiﬁcant (P  0.69). Mean du-
ration of type 1 diabetes in patients with
nephropathy (18.3  7.8 years) was not
different from the duration in patients
without nephropathy (15.1  6.4 years,
P  0.24).
We found no signiﬁcant differences
of CVR values between the subgroups of
patients with type 1 diabetes distin-
guished on the basis of the presence of
diabetic retinopathy, neuropathy, hyper-
tension, and hyperlipidemia. Addition-
ally, no differences regarding VMRr or
BHI were found between groups of pa-
tients distinguished on the basis of use of
statins or ACE inhibitor/angiotensin re-
ceptor blocker (Table 3).
The multivariable regression analysis
conﬁrmed a signiﬁcant inverse associa-
tion between diabetic microalbuminuria/
nephropathy and VMRr independently
from other vascular risk factors or type 1
diabetes–related organ damage (Table 4).
CONCLUSIONS — Our study shows
a reduction of VMRr and BHI in patients
with type 1 diabetes, who were free of
overt cerebrovascular events. These CVR
parametersweresigniﬁcantlylowerinthe
subgroup of patients with diabetic ne-
phropathy. However, CVR was not asso-
ciated with diabetes course, presence of
additional risk factors, biochemical pa-
rameters, and intima-media thickening.
We revealed that the presence of dia-
betic nephropathy can indicate subclini-
cal cerebrovascular pathology in patients
with type 1 diabetes independently from
other micro- and macroangiopathy evi-
dence. Our ﬁndings are in line with
resultsofapreviousstudy,whichdemon-
strated a close relationship between in-
dexes of cerebral microangiopathy (PI
and CVR) and microalbuminuria in pa-
tientswithtype2diabetes(19).Fewstud-
ies have reported an association between
CVR and diabetic retinopathy in both
type1andtype2diabetes(7,13).Wealso
Table 2—Comparison of the middle cerebral artery blood ﬂow parameters and IMT between
patients with type 1 diabetes and healthy control subjects
Patients Healthy control subjects P
n 59 30
Resting Vmean (cm/s) 60.7 (35.7–106.5) 57.3 (36.8–85.9) 0.27
PI 0.88 (0.65–1.52) 0.89 (0.67–1.20) 0.19
RI 0.81 (0.44–0.75) 0.57 (0.49–0.69) 0.36
VMRr (%) 82.9 (39–143) 100 (52–142) 0.006
BHI 1.62 (0.42–3.41) 2.18 (0.89–3.63) 0.045
Delta etCO2 HV (%) 1.65 (1.0–2.5) 1.75 (1.0–3.0) 0.23
Delta etCO2 BH (%) 1.1 (0.5–2.0) 1.1 (0.7–1.8) 0.94
IMT (mm) 0.35 (0.26–0.64) 0.30 (0.21–0.43) 0.001
Dataaremedian(range).etCO2HV,endtidalCO2duringhyperventilation;etCO2BH,endtidalCO2
during breath holding.
Table 3—Impact of vascular risk factors and comorbidities on CVR parameters in patients
with type 1 diabetes
VMRr (%) BHI
n Present Absent P Present Absent P
Hyperlipidemia 36 80.8 88.8 0.5 1.62 1.65 0.2
Hypertension 10 80.6 83.0 0.90 1.65 1.67 0.88
Neuropathy 12 82.5 81.5 0.49 1.58 1.65 0.34
Retinopathy 26 82.3 92.3 0.09 1.47 1.72 0.08
Nephropathy 10 73.9 83.5 0.029 1.37 1.69 0.036
ACE inhibitor or angiotensin receptor
blocker treatment
9 77.6 83.2 0.32 1.61 1.65 0.56
Statin treatment 4 77.1 82.7 0.31 1.50 1.62 0.36
Data are median values.
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niﬁcancetowardaCVRimpairmentinthe
presence of diabetic retinopathy. How-
ever, lack of statistical signiﬁcance can
probably be explained by type 2 error be-
cause of the small sample size. Interest-
ingly, the relationship between CVR and
nephropathy in our patients was not inﬂu-
enced by hypertension, a ﬁnding that has
also been described in former studies on
type 1 and type 2 diabetes (6,13). Fur-
thermore, we did not ﬁnd any relation-
ship between the use of antihypertensive
or statin treatment and CVR in our pa-
tients, although statin and ACE inhibitor
treatments were reported as potential
CVR confounders (20,21). The lack of
confounder effects can be explained by
the relatively small sample size in our
study.
The lack of correlation between IMT
and CVR seen in our study has also been
observed in patients with type 2 diabetes
(13). To our best knowledge, no pub-
lished data exist on this correlation in pa-
tients with type 1 diabetes. However,
recently published research showed neg-
ative correlation of cerebrovascular reac-
tivity to L-arginine with IMT. This
approach may be an alternative method
for analysis of CVR and IMT relationship
in patients with type 1 diabetes (22).
Theprovocationmethodsusedinour
study to estimate the reactivity of cerebral
vessels (hyperventilation and breath-
holding tests) have not been published
yet for the adult patients with type 1 dia-
betes.Advantagesofthisapproacharethe
simulation of the natural cerebrovascular
autoregulation mechanisms resulting
from the use of a physiological method of
evoking changes in pCO2, safety, nonin-
vasiveness, and lack of side effects. The
VMRr enabled us to assess a full range of
vasodilation, instead of assessing only the
upper limit obtained during the hyper-
capnia, as it was previously published in
patientswithtype1diabetes(5–6,8).The
useofthesetestsallowedustodetectCVR
impairment in the whole group of pa-
tients and not only in subgroups with
longer duration of type 1 diabetes or with
higher complications rate, as it was previ-
ously presented (5–7). Also, to avoid a
possible inﬂuence of smoking and hor-
monal replacement therapy on CVR, we
limited our study to nonsmokers and
nonhormonal users (23,24). In previous
studies, the confounding effects of smok-
ing and hormonal therapy were not con-
trolled (6,13).
Asalimitationofthepresentedstudy,
we should mention that a relatively small
sample size allowed us to detect only a
single factor that has a signiﬁcant impact
on CVR in the examined group patients.
The correlation between the presence of
diabeticretinopathyandthelowCVRval-
ues found in some studies could not be
conﬁrmed by our data (6,7). However,
both the univariate and multivariate anal-
yses have shown statistically signiﬁcant
correlation between diabetic nephropa-
thy and CVR impairment. This trend is
also in agreement with previously pub-
lished data (7,19). Despite a relatively
large proportion of hyperlipidemic pa-
tients in our study, no inﬂuence of hyper-
lipidemia on CVR was found, similar to
previous reports (6,25). The presence of
clinically asymptomatic CVR impairment
inagroupofpatientswithtype1diabetes
and peripheral microcirculatory dysfunc-
tion is an argument for early implementa-
tion of primary stroke prevention in these
patients.
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